Epigenetics in liver disease

Hepatology

Volumn 60, Issue 4, 2014, Pages 1418-1425

  Mann, Derek A ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; UNTRANSLATED RNA; CHROMATIN; HISTONE;

ADENOSINE DIPHOSPHATE RIBOSYLATION; ARTICLE; CELL ADHESION; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL TRANSDIFFERENTIATION; CELL TRANSFORMATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN STRUCTURE; DNA HISTONE INTERACTION; DNA METHYLATION; DNA MODIFICATION; EPIGENETICS; GENE ACTIVATION; GENE CONTROL; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HISTONE CODE; HUMAN; LIVER CELL CARCINOMA; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATIENT CARE; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; CHROMATIN; DISEASE MANAGEMENT; GENETICS; LIVER DISEASES; PATHOPHYSIOLOGY; PHYSIOLOGY; TRENDS;

CHROMATIN; DISEASE MANAGEMENT; DNA METHYLATION; EPIGENOMICS; HISTONES; HUMANS; LIVER DISEASES; RNA, UNTRANSLATED; TRANSCRIPTION, GENETIC;

EID: 84904795250     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27131     Document Type: Article

References (59)

1. Cedar H, Bergman Y. Programming of DNA methylation patterns. Annu Rev Biochem 2012;81:97-117.
2. Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009;15:930-935.
3. Heyn H, Moran S, Herraez-Hernando I, Sayols S, Gomez A, Sandoval J, et al. DNA methylation contributes to natural human variation. Genome Research 2013 [Epub ahead of print].
4. Black JC, Van Rechem CV, Whetstine JR. Histone lysine methylation dynamics: establishment, regulation and biological impact. Mol Cell 2012;48:491-507.
5. Talbert PB, Henikoff S. Histone variants - ancient wrap artists of the epigenome. Nat Rev Mol Cell Biol 2010;11:264-275.
6. Clapier CR, Cairns BR. The biology of chromatin remodeling complexes. Annu Rev Biochem 2009;78:273-340.
7. Margueron R, Reinberg D. The polycomb complex PRC2 and its mark in life. Nature 2011;469:343-349.
8. Kemper JK. Regulation of FXR transcriptional activity in health and disease: emerging roles of FXR cofactors and post-translational modifications. Biochem Biophys Acta 2011;1812:842-850.
9. Huang S, He X. The role of microRNAs in liver cancer progression. Br J Cancer 2011;104:235-240.
10. He Y, Huang C, Zhang S, Sun X, Long X, Li J. The potential of microRNAs in liver fibrosis. Cell Signal 2012;24:12.
11. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet 2011;12:136-149.
12. Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet 2009;10:155-159.
13. Stefanska B, Huang J, Bhattacharyya B, Suderman M, Hallett M, Han ZG, et al. Definition of the landscape of promoter DNA hypomethylation in liver cancer. Cancer Res 2011;71:5891-5903.
14. Shen J, Wang S, Zhang YJ, Kappil M, Wu HC, Kibriya MG, et al. Genome-wide aberrant DNA methylation profiles in hepatocellular carcinoma. Hepatology 2012;55:1799-1808.
15. Song MA, Tiirikainen M, Kwee S, Okimoto G, Yu H, Wong LL. Elucidating the landscape of aberrant DNA methylation in hepatocellular carcinoma. PLoS One 2013;85:5761.
16. Nishida N, Kudo M, Nagasaka T, Ikai I, Goel A. Characteristic patterns of altered DNA methylation predict emergence of human hepatocellular carcinoma. Hepatology 2012;56:994-1003.
17. Park IY, Sohn BH, Yu E, Suh DJ, Chung YH, Lee JH. Aberrant epigenetic modifications in hepatocarcinogenesis induced by hepatitis B virus X protein. Gastroenterology 2007;132:1476-1494.
18. Huang J, Wang Y, Guo Y, Sun S. Down-regulation of microRNA-152 induces aberrant DNA methylation in hepatitis B virus-related hepatocellular carcinoma by targeting DNA methyltransferase 1. Hepatology 2010;52:60-70.
19. Higgs MR, Lerat H, Pawlotsky JM. Downregulation of Gadd45beta expression by hepatitis C virus leads to defective cell cycle arrest. Cancer Res 2010;70:4901-4911.
20. Li M, Zhao H, Wood LD, Anders RA, Choti MA, Pawlik TM, et al. Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet 2011;43:828-829.
21. Huang J, Deng Q, Wang Q, Li KY, Dai JH, Li N, et al. Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. Nat Genet 2012;44:1117-1121.
22. Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, et al. Integrated analysis of somatic mutations and focal copy-number identifies key genes and pathways in hepatocellular carcinoma. Nat Genet 2012;44:694-698.
23. Cleary S, Jeck WR, Zhao X, Chen K, Selitsky SR, Savich GL, et al. Identification of driver genes in hepatocellular carcinoma by exome sequencing. Hepatology 2013 [Epub ahead of print].
24. Au SL, Wong CC, Lee JM, Fan DN, Ni IO, Wong CM. Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis. Hepatology 2012;56:622-631.
25. Fan DN, Tsang FH, Tam AH, Au SL, Wong CC, Wei L, et al. Histone lysine methyltransferase, suppressor of variegation 3-9 homolog 1, promotes hepatocellular carcinoma progression and is negatively regulated by microRNA-125b. Hepatology 2013;57:637-647.
26. Tsai WC, Hsu SD, Hsu CS, Lai TC, Chen SJ, Shen R, et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest 2012;122:2884-2897.
27. Hsu SH, Wang B, Kota J, Yu J, Costinean S, Kutay H, et al. Essential metabolic, anti-inflammatory and anti-tumorigenic functions for mir-122 in liver. J Clin Invest 2012;122:2871-2883.
28. Song K, Han C, Zhang J, Lu D, Dash S, Feitelson M, et al. Epigenetic regulation of miR-122 by PPARγ and hepatitis B virus X protein in hepatocellular carcinoma cells. Hepatology 2013 [Epub ahead of print].
29. Panzitt K, Tschermatsch MM, Guelly C, Moustafa T, Stradner M, Strohmaeir HM, et al. Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology 2007;132:330-342.
30. Matouk IJ, Abbasi I, Hochberg A, Galun E, Dweick H, Akkawi M. Highly upregulated in liver cancer noncoding RNA is overexpressed in hepatic colorectal metastasis. Eur J Gastroenterol Hepatol 2009;21:688-692.
31. Yang Z, Zhou L, Wu LM, Lai MC, Xie HY, Zhang F, et al. Overexpression of long noncoding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplant. Ann Surg Oncol 2011;18:1243-1250.
32. Geng YJ, Xie SL, Li Q, Ma J, Wang GY. Large intervening noncoding RNA HOTAIR is associated with hepatocellular carcinoma progression. J Int Med Res 2011;39:2119-2128.
33. Lai MC, Yang Z, Zhou QQ, Xie HY, Zhang F, Wu LM, et al. Long noncoding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplant. Med Oncol 2012;29:1810-1816.
34. Waddington CH. The strategy of the genes; a discussion of some aspects of theoretical biology. London: Allen & Unwin; 1957.
35. Hernández-Gea V, Ghiassa-Nejad Z, Rozenfeld R, Gordon R, Fiel MI, Yue Z, et al. Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues. Gastroenterology 2012;142:938-946.
36. Mann J, Oakley F, Akiboye F, Elsharkawy A, Thorne A, Mann DA. Regulation of myofibroblast transdifferentiation by DNA methylation and MeCP2: implications for wound healing and fibrogenesis. Cell Death Differ 2007;14:275-285.
37. Mann J, Chu DC, Maxwell A, Oakley F, Zhu NL, Tsukamoto H, Mann DA. MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis. Gastroenterology 2010;138:705-714.
38. Hu B, Gharaee-Kermani M, Wu Z, Pahn SH. Essential role of MeCP2 in the regulation of myofibroblast differentiation during pulmonary fibrosis. Am J Pathol 2011;178:1500-1508.
39. Perugorria MJ, Wilson CL, Zeybel M, Walsh M, Amin S, et al. Histone methyltransferase ASH1 orchestrates fibrogenic gene transcription during myofibroblast transdifferentiation. Hepatology 2012;56:1129-1139.
40. Yang JJ, Tao H, Huang C, Shi KH, Ma TT, et al. DNA methylation and MeCP2 regulation of PTCH1 expression during rats hepatic fibrosis. Cell Signal 2013;25:1202-1211.
41. Murphy SK, Yang H, Moylan CA, Pang H, Dellinger A, et al. Relationship between the methylome and transcriptome in patients with non-alcoholic fatty liver disease. Gastroenterology 2013 [epub ahead of print].
42. Chen SL, Zheng MH, Shi KQ, Yang T, Chen YP. A new strategy for treatment of liver fibrosis: letting MicroRNAs do the job. BioDrugs 2013;27:25-34.
43. Doliney DC, Wiedman JR, Waterland RA, Jirtle RL. Maternal genistein alters coat color and protects Avy mouse offspring from obesity by modifying the fetal epigenome. Environ Health Perspect 2006;114:567-572.
44. Pogrigbny IP, Tryndyak VP, Bagnyukova TV, Melnyk S, Montgomery B, Ross SA, et al. Hepatic epigenetic phenotype predetermines individual susceptibility to hepatic steatosis in mice fed a lipogenic methyl-deficient diet. J Hepatol 2009;51:176-186.
45. Cordero P, Campion J, Milagro FI, Martinez JA. Dietary supplementation with methyl donor groups could prevent nonalcoholic fatty liver. Hepatology 2011;53:2151-2152.
46. Inoue I, Shinod Y, Ikeda M, Hayashi K, Kanazawa K, et al. CLOCK/BMAL1 is involved in lipid metabolism via transactivation of the peroxisome proliferator-activated receptor (PPAR) response element. J Atheroscler Thromb 2005;12:169-174.
47. Bellet MM, Sassone-Corsi P. Mammalian circadian clock and metabolism - the epigenetic link. J Cell Sci 2010;123:3837-3848.
48. Plfuger PT, Herranz D, Velasco-Miguel, Serrano M, Tschöp MH. Sirt1 protects against high-fat diet-induced metabolic damage. Proc Natl Acad Sci U S A 2008;105:9793-9798.
49. Haus E, Smolensky M. Biological clocks and shift work: circadian dysregulation and potential long-term effects. Cancer Causes Control 2006;17:489-500.
50. Ahrens M, Ammerpohl O, von Schönfels W, Kolarova J, Bens S, et al. DNA methylation analysis in nonalcoholic fatty liver disease suggests distinct disease-specific and remodeling signatures after bariatric surgery. Cell Metab 2013;18:296-302.
51. Tian W, Xu H, Fang F, Chen QI, Xu Y, Shen A. Brahma-related gene 1 bridges epigenetic regulation of proinflammatory cytokine production to steatohepatitis in mice. Hepatology 2013;58:576-588.
52. Yu-Yuan L. Genetic and epigenetic variants influencing the development of nonalcoholic fatty liver disease. World J Gastroenterol 2012;18:6546-6551.
53. Esau C, Davis S, Murray SF, Yu XX, Pandey SK, et al. miR-122 regulation of lipid metabolism revealed by in vitro antisense targeting. Cell Metab 2006;3:87-98.
54. Carone BR, Fauquier L, Habib N, Shea JM, Hart CE, et al. Paternally induced transgenerational environmental reprogramming of metabolic gene expression in mammals. Cell 2010;143- 1084-96.
55. Zeybel M, Hardy T, Wong YK, Mathers JC, Fox CR, et al. Multigenerational epigenetic adaptation of the hepatic wound-healing response. Nat Med 2012;18:1369-1377.
56. Veenendaal MV, Painter RC, de Rooij SR, Bossuyt PM, van der Post JA, et al. Transgenerational effects of prenatal exposure to the Dutch famine on neonatal adiposity and health in later life. BJOG 2013;120:548-553.
57. Kelly TK, De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets. Nat Biotech 2010;28:1069-1078.
58. Bader AG. miR-34 - a microRNA replacement therapy is headed to the clinic. Front Genet 2012;3:1-9.
59. Subramanian S, Bates SE, Wright JJ, Espinoza-Delgado I, Piekarz RL. Clinical toxicities of histone deacetylase inhibitors. Pharmaceuticals 2010;3:2751-2767.